Park Ha Biological Technology Co., Ltd. shares fall 2.91% after-hours as Opus Genetics doses first patient in pivotal LYNX-3 trial.

Park Ha Biological Technology Co., Ltd. declined 2.91% in after-hours trading. Opus Genetics, Inc. announced that the first patient has been dosed in LYNX-3, the Company’s pivotal Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% in treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision. The trial has Fast Track designation from the FDA and is being conducted under a Special Protocol Assessment (SPA). Positive topline results are expected.